Deregulation of cell signaling homeostasis is a predominant feature of cancer initiation and progression. Transforming growth factor β (TGFβ) is a pleiotropic cytokine, which regulates numerous biological processes of various tissues in an autocrine and paracrine manner. Aberrant activity of TGFβ signaling is well known to play dual roles in cancer, depending on tumor stage and cellular context. The crucial roles of TGFβ in modulating the tumor microenvironment, its contribution to the accumulation of mechanical forces within the solid constituents of a tumor and its effects on the effective delivery of drugs are also becoming increasingly clear. In this review, we discuss the latest advances in the efforts to unravel the effects of TGFβ signaling in various components of the tumor microenvironment and how these influence the generation of forces and the efficacy of drugs. We also report the implications of tumor mechanics in cancer therapy and the potential usage of anti-TGFβ agents to enhance drug delivery and augment existing therapeutic approaches. These findings provide new insights towards the significance of targeting TGFβ pathway to enhance personalized tumor treatment.
The crucial role of transforming growth factor β (TGFβ) in tumor progression, metastasis and treatment has been well recognized and has become the topic of extensive research. Among the effects, TGFβ can regulate cancer cell proliferation, contribute to epithelial-to-mesenchymal transition (EMT), suppress the function of immune cells compromising immune response, contribute to the conversion of fibroblasts to myofibroblasts and cause overproduction of extracellular matrix (ECM) in the tumor. While it has been known for over two decades that anti-cancer drugs cannot penetrate deep into collagen-rich tumors (e.g., pancreatic cancers) and, more significantly, that depletion of collagen fibers can improve drug delivery, only recently TGFβ has become a target to reduce tumor fibrosis and thus, increase intratumoral drug concentration and treatment efficacy. Preclinical data of this new strategy are promising and it has already reached clinical trials. In this review, we first present a brief description of TGFβ synthesis and activation along with its signaling pathways. Following, we discuss the effects of TGFβ on tumor progression, its pathway alterations in cancer as well as its effects on EMT, immune cells function, fibroblasts behavior and ECM remodeling. Finally, based on the above, we review the barriers to the effective delivery of drugs caused by TGFβ and how regulation of TGFβ signaling can be employed to optimize delivery of therapeutic agents and overall survival (1–3).
2. TGFβ synthesis and activation
The TGFβ superfamily encompasses around 40 secreted cytokines, including TGFβ, bone morphogenetic proteins (BMPs), activins, nodal, lefty, myostatin, anti-Müllerian hormone (AMH) and growth differentiation factors (GDFs). These cytokines regulate a plethora of biological functions such as cell proliferation and apoptosis, embryonic patterning, stem cell maintenance, cell differentiation, migration and immune surveillance. Importantly, the effects of these factors are characterized as cell-type specific as well as context dependent (1–3). The TGFβ isoforms, with most common being TGFβ1, 2 and 3, are initially synthesized as 75 kDa inactive homodimers, known as pro-TGFβ, which consist of TGFβ associated with latency-associated proteins (LAPs) at the N-terminal part of the pro-peptide. This is part of the TGFβ large latent complex (LLC), comprised of the LAPs and the latency TGFβ-binding proteins (LTBPs) (4–7), and is covalently associated to the ECM via the N-terminal region of LTBPs (8,9) (Fig. 1). While TGFβ is part of the LLC complex, it remains in an inactive form since the high affinity association of LAPs with TGFβ prevents the interaction with its receptors (10). During TGFβ activation, LAPs undergo conformational changes induced by thrombospondin-1 (TSP-1) (11,12) followed by cleavage mediated by furin convertase, plasmin or matrix metalloproteinases MMP-2/9 resulting in the release of the mature 24 kDa TGFβ dimer (13–15). The active ligand is then able to bind and activate TGFβ receptors (TGFβRs) to propagate downstream intracellular signaling events. Therefore, the processing of pro-TGFβ into the active TGFβ ligand is a critical regulatory step which determines its bioavailability.
3. TGFβ signaling pathways
The TGFβ and TGFβ-like cytokines mediate downstream intracellular signaling via the Smad family of proteins, which consists of eight human structurally related members (16–20) (Fig. 1). Smads can be functionally classified into three groups: the receptor activated Smads (R-Smads), which include Smad1, 2, 3, 5, 8; the common mediator Smad (Co-Smad), Smad4; and the inhibitory Smads (I-Smads), Smad6 and 7 (17,21). Three types of TGFβRs are responsible for initiating signaling; TGFβRI, II and III. There are seven TGFβRI, five TGFβRII and two TGFβRIII known so far. TGFβRIs include activin receptor-like kinases 1–7 (ALK1–7), TGFβRIIs include the TGFβRII, bone morphogenetic protein receptor II (BMPRII), activin receptor II (ACTRII), ACTRIIB, anti-Müllerian hormone receptor II (AMHRII), while beta-gycan and endoglin belong to the TGFβRIIIs (22) and mostly function as co-receptors to enhance activin signaling (23). In most tissues, TGFβ ligands function through heteromeric complex formation between two TGFβRI and two TGFβRII molecules. While both receptors possess Ser/Thr kinase activity, TGFβRIIs function as the ‘activator’ and TGFβRIs as the ‘signal propagating’ component (24). The TGFβRII-ALK5 complex transduces the signal from all three TGFβ isoforms in multiple cell types, whereas association of TGFβRII with ALK1 is involved in endothelial cells and with ALK2 in cardiovascular tissues (25). ALK5 activates Smad2 and 3 via the canonical TGFβ signaling pathway whereas ALK2, 3 and 6 can activate Smad1, 5 and 8, which are transducers of the BMP signaling pathway (26,27). The TGFβ signaling pathways can be classified in two major categories; the canonical or Smad-dependent and the non-canonical or Smad-independent pathways.
Canonical pathway (Smad-dependent)
Even though TGFβ isoforms may elicit diverse cellular responses, they all activate signaling via a similar sequence of events. Binding of the active TGFβ1 ligand to the Ser/Thr kinase TGFβRII followed by recruitment of the ALK5 (TGFβRI) on the cell surface initiates intracellular signaling. Within the heterotetrameric receptor-ligand complex formed, TGFβRII phosphorylates TGFβRI allowing it to interact with the R-Smads (Smad2/3) which, in turn, become phosphorylated at the conserved SSXS C-terminal motif (28,29). Recruitment of R-Smads to the activated TGFβRI is facilitated by Smad anchor for receptor activation (SARA) protein (30). Subsequently, this triggers the formation of a heterotrimeric complex between phosphorylated R-Smads (Smad2/3) and Co-Smad (Smad4), which can translocate into the nucleus to regulate gene expression (3) (Fig. 1). Smads can differentially modulate gene expression by acting as transcription factors in co-operation with co-activators, such as p300/CREB-binding protein (CBP), p300/CBP-associated factor (PCAF), Smad4-interacting factor (SMIF), forkhead transcription factors 1, 3, 4 (FoxO1/3/4), specificity protein 1 (Sp1), c-Jun/c-Fos, Sertad1, or co-repressors, such as E2F4/5-p107, activating transcription factor 3 (ATF3), TGFβ-induced factor (TGIF), Ski, SnoN, forkhead transcription factor G1 (FoxG1), ecotropic viral integration site 1 protein (EVI1) and C-terminal binding protein (CTBP) (28,31–47). In addition, Smads are able to epigenetically regulate gene expression either by inducing chromatin remodeling (48,49) or by maintaining DNA methylation and silencing of selected genes (50). Importantly, the I-Smad, Smad7, is a key target gene induced by TGFβ signaling and acts as negative feedback regulator of the pathway (51). In the absence of TGFβ stimulation, Smad7 resides in the cell nucleus and translocates to the plasma membrane upon TGFβ-mediated receptor activation (52). Smad7 is then able to interfere and block interactions between the R-Smads and the activated receptors to inhibit downstream signaling events (53). In addition, Smad7 can target the TGFβRs for proteasomal degradation via the E3-ubiquitin ligases Smurf1 and 2 (54,55). Finally, Smad7 antagonizes the formation of a functional Smad-DNA complex by directly binding to DNA via its MH2 domain and therefore blocks TGFβ-mediated transcriptional responses (56).
Non-canonical pathways (Smad-independent)
It is also well established that TGFβ-mediated effects can also be exerted through non-canonical Smad-independent pathways (57). TGFβ has been shown to induce activation of Erk signaling in various tissues including epithelial and endothelial cells, fibroblasts, breast and colorectal cancer cells in order to promote disassembly of adherens junctions and cell migration (58–64). TGFβRI phosphorylation can recruit and activate ShcA, thus promoting the formation of a ShcA/Grb2/Sos complex. In turn, this complex is able to activate Ras on the plasma membrane followed by sequential activation of c-Raf, MEK and Erk (65).
Moreover, TGFβ can mediate the activation of the c-Jun N-terminal kinase (JNK) and p38/mitogen-activated protein kinase (MAPK) pathways, which are responsible for promoting apoptosis or cell migration depending on cellular context (66–68), via the mitogen-activated protein kinase kinase (MKK)4 and 3/6, respectively (69,70). Further upstream, MKKs are phosphorylated by the TGFβ-activated kinase 1 (TAK1) (71,72) which is recruited to the TGFβRs via the scaffold protein TNF receptor-associated factor 6 (TRAF6) (73,74). Besides TAK1, two other mitogen-activated protein kinase kinase kinases (MAPKKKs), namely MEKK1 and mixed lineage kinase 3 (MLK3), were also shown to mediate TGFβ-induced activation of JNK and p38-MAPK by MKK4 and 3/6 (75,76).
The Rho-like small GTPases, predominantly RhoA, Rac and cell division cycle 42 (cdc42), are additional molecules that mediate important TGFβ cellular functions, such as cytoskeletal organization, cell polarity, cell migration and gene expression (77). TGFβ is able to rapidly activate the RhoA and cdc42/Rac1 pathways, in a Smad2/3-independent manner, to promote actin polymerization, formation of stress fibers and EMT (78,79). TGFβ may also downregulate RhoA protein levels by recruitment of Par6 at the TGFβRI–II complex. Phosphorylation of Par6 by TGFβRII triggers binding of the E3 ligase Smurf1 to the complex followed by ubiquitination and degradation of RhoA at sites of cellular protrusions. Subsequently, this leads to the dissolution of tight junctions, rearrangement of actin cytoskeleton and EMT (80).
Some of the effects exerted by TGFβ could also be mediated by activation of the phosphatidylinositol-4,5-bisphosphate 3-kinase/Akt (PI3K/Akt) pathway. This is evident from studies showing that TGFβ can rapidly induce PI3K activation followed by phosphorylation of its effector Akt to promote EMT, cell migration and survival (81,82). One of the most important effector molecules downstream of PI3K/Akt pathway appears to be the mammalian target of rapamycin (mTOR), a key regulator of protein synthesis, which can subsequently phosphorylate S6 kinase (S6K) and eukaryotic initiation factor 4E-binding protein 1 (4EBP1) (83). Activation of the mTOR pathway by TGFβ is thought to be important for regulating cell size, EMT and invasion (84) (Fig. 1).
4. TGFβ signaling in cancer initiation and tumor progression
It is well established that the multipotent actions of TGFβ are highly context dependent. The complexity of these functions is increased due to the fact that TGFβ exerts distinct effects depending on the tissue type as well as the genetic and epigenetic background of cells (85). It is clearly evident that TGFβ plays dual roles during carcinogenesis. In early stages TGFβ promotes growth inhibition and apoptosis of normal epithelial and lymphoid cells as well as pre-malignant tumors, whereas during late stages TGFβ acquires pro-oncogenic and pro-metastatic roles, which are associated with a progressive increase in the locally secreted TGFβ levels (86–88). Therefore, one of the hallmarks of cancer is that the vast majority of cases exhibits insensitivity to TGFβ-mediated growth inhibition.
Regulation of cell proliferation
It has long been noted that TGFβ has a cytostatic effect on normal epithelial (89), endothelial (90,91) and neuronal cells (92) as well as certain cells of the immune system, such as T cells (93). These functions of TGFβ are extremely important for physiological tissue homeostasis in order to restrain cell proliferation and prevent the generation of hyperproliferative disorders, like cancer. These anti-proliferative effects primarily control the G1/S phase transition events (94) and are mediated via induction of the cyclin-dependent kinase inhibitors CDKN2B (encoding p15/INK4B) (95), CDKN1A (encoding p21/Cip/Waf1) (96) and p27/Kip1 (97) by TGFβ. Cell cycle arrest can also be achieved by repression of the proliferation-inducing transcription factors c-Myc (98) and the family of inhibitor of DNA-binding proteins ID1, 2 and 3 (36,99). On the other hand, the effects of TGFβ in proliferation can be opposing, depending on the tissue type. It is also well recognized that TGFβ enhances proliferation of fibroblasts (89) and it is often mediated indirectly by TGFβ-induced connective tissue growth factor (CTGF) secretion, which is responsible for stimulating fibroblast proliferation and ECM synthesis (100). It is now unambiguously accepted that cancer-associated fibroblasts (CAFs) play critically important roles in the tumor microenvironment and cancer progression and their functions are further discussed below.
Pathway alterations in human cancers
Numerous human studies have identified that components of the TGFβ pathway become genetically or epigenetically altered in various tumor types thus explaining, at least in part, the escape from TGFβ-mediated growth control. Loss of function or truncating mutations in TGFβRI and TGFβRII as well as in Smad2 and Smad4 have been detected in colorectal, pancreatic, gastric and prostate cancers (18,101–105). In addition, loss of the 18q21 chromosome region, harboring the Smad4 gene, is commonly observed in ~60% of pancreatic and 30% of colorectal cancers (106–109) has been shown to promote angiogenesis and tumor growth by inducing vascular endothelial growth factor (VEGF) expression (60,110). However, in other tumor types like breast, the frequency of Smad gene mutations is rare (18,104,105) suggesting that alternative mechanisms for acquiring resistance to growth inhibition by TGFβ exist. These include activation of the Ras oncogene which leads to Erk-mediated Smad2/3 phosphorylation and suppression of functional Smad complex formation (111–113). Furthermore, overexpression of the dominant-negative CCAAT/enhancer-binding protein β (C/EBPβ) isoform LIP in breast cancer patients was found to suppress TGFβ-mediated growth inhibition (114). Finally, another mechanism which TGFβ may exploit in order to switch from a tumor suppressor to a metastasis-promoting factor is through differential regulation of the ID1 gene. While ID1 expression is suppressed by TGFβ in normal tissues, it was found to be induced in patient-derived metastatic breast cancer cells (115).
EMT and cancer metastasis
EMT is an integral process during embryonic development which can be abnormally reactivated in adult tissues under pathological conditions, such as cancer and fibrosis (116). It involves the activation of a coordinated reversible transcriptional program whereby epithelial cells undergo dissolution of cell junctions, lose their polarity and epithelial characteristics concomitantly with acquisition of mesenchymal features and dramatic remodeling of their cytoskeleton. During this process, the expression of epithelial genes, such as E-cadherin, γ- and β-catenin, zonula occludens (ZO), and claudins is suppressed with concurrent expression of mesenchymal components, such as N-cadherin, vimentin, fibronectin and α-smooth muscle actin (α-SMA) (50,117,118). This program can be initiated by several pleiotropically acting transcription factors regulated by signaling pathways such as TGFβ, Wnt and receptor tyrosine kinases (RTKs). Some of the better characterized examples include Snail (119), Slug (120), zinc-finger E-box binding homeobox 1 (ZEB1/δEF1) (121), zinc-finger E-box binding homeobox 2/Smad interacting protein 1 (ZEB2/SIP1) (122), Twist (117), high mobility group AT-hook 2 (HMGA2) (123) and forkhead box protein C2 (FOXC2) (124). In addition, recent studies indicate that overactive TGFβ-TGFβR-Smad2 signaling axis could further contribute to the establishment of an EMT phenotype by maintaining the epigenetic silencing of epithelial genes during this process (50). Besides Smads, other signaling pathways have also been implicated in TGFβ-induced EMT, including Erk, PI3K/Akt, RhoA, p38-MAPK and cofilin (125–127). Induction of EMT is one of the major mechanisms by which TGFβ has been shown to promote cell motility, invasiveness and metastasis of cancer cells (128). EMT significantly enhances intravasation of carcinoma in situ cells through the basement membrane, survival in the circulation, extravasation at the distal tissues and formation of micrometastases in secondary organs (116,117,129).
5. The effects of TGFβ on the tumor microenvironment
Under physiological conditions, the sustained local release of basal TGFβ levels is sufficient to maintain normal tissue homeostasis. However, under conditions of tissue injury, the local TGFβ secretion from stromal cells and blood platelets is rapidly increased to facilitate wound repair as well as to prevent uncontrolled regenerative cell proliferation and inflammation (130,131). A similar situation is commonly observed in pre-malignant tumors where TGFβ is secreted in the microenvironment initially to control proliferation and cancer progression, but it is ultimately utilized by cancer cells to promote their malignant properties. Local TGFβ release produces a tumor microenvironment which is conducive to tumor growth, invasion and metastasis (132). Secretion of TGFβ can be derived from epithelial cancer cells thus regulating their own properties within the tumor mass in an autocrine or paracrine fashion (125). Moreover, infiltrating stromal cells, including fibroblasts, leukocytes, macrophages, bone-marrow derived endothelial, mesenchymal and myeloid precursor cells, is another major source of this cytokine (133). Finally, TGFβ can be stored in the ECM of the bone and can be activated during development of osteolytic metastatic lesions (134). In the following paragraphs, we summarize the effects of TGFβ on the main and better characterized components of the tumor microenvironment and particularly on fibroblasts, immune cells and the ECM.
Effect of TGFβ on immune cells
TGFβ exhibits immunosuppressive effects on all arms of the immune system because it functions as antagonist of several functions of the immune cells (132,135). As a result, the anti-tumor immune response is compromised, reducing cancer cell recognition and clearance. Specifically, TGFβ affects the function of natural killer cells, CD4+ and 8+ T cells, macrophages, neutrophils, dendritic, mast and B cells (136–138). Specifically, a TGFβ-rich tumor microenvironment is a suppressor of T-cell proliferation, reduces their effector function and inhibits the maturation of T helper cells (137,139,140). It also induces macrophage M2 polarization from a type I to a type II phenotype, which hinders the suppression of monocyte-mediated cell death, reduces effector function and increases chemotaxis (141,142). Additionally, TGFβ induces an N2 neutrophil phenotype which, as with the macrophages, reduces effector function and increases secretion of inflammatory cytokines (143). Finally, high levels of TGFβ can cause apoptosis of B cells, inhibit the maturation of dendritic and natural killer cells and induce chemotaxis of mast cells (144–146). The combined immuno-suppressive effects of TGFβ compromise the ability of the host to resist tumor progression and thus consist a barrier to immunotherapy.
Effect of TGFβ on fibroblasts
A primary role of TGFβ in modulating the tumor microenvironment is its contribution to the conversion of fibroblasts to myofibroblasts, also known as CAFs (147,148). Specifically, the compressive forces developed inside a tumor, due to its growth in the confined space of the host tissue, can facilitate the conversion of fibroblasts to proto-myofibroblasts. Subsequently, TGFβ increases the levels of collagens I and III and fibronectin, which promote cellular adhesion to extracellular fibers, and thus, enhances the communication of mechanical signals between the ECM of the tumor and the fibroblasts (149,150). As a result, the mechanical forces are more actively transmitted in the interior of the cell and contribute to the conversion of proto-myofibroblasts to differentiated myofibroblasts. Myofibroblasts are characterized by more extensively developed stress fibers in the cytoskeleton compared to proto-myofibroblasts, presumably to balance the extracellular forces, and by the de novo expression of α-SMA. The contraction of myofibroblasts is sustained by α-SMA stress fibers and it is regulated by Rho/ROCK signaling activation. The produced contractile forces remodel the ECM due to the ability of fibroblasts to stretch collagen fibers and produce ECM molecules (151,152). Additionally, these forces can be transmitted to the LLC via integrins. LLC is also bound to extracellular fibers (Fig. 1), which resists the pulling of the LLC by myofibroblasts and gives rise to a mechanically-induced liberation of TGFβ (147). The stiffer the ECM, the stronger the interactions among myofibroblasts, LLC and extracellular fibers and thus, the release of TGFβ becomes more pronounced. Therefore, myofibroblast contraction within a collagen-rich, and thus, stiff microenvironment further stimulates the release of active TGFβ from its latent form.
Effect of TGFβ on ECM
TGFβ upregulates the expression and synthesis of many matrix proteins, primarily through the recruitment of myofibroblast. Proteins upregulated by TGFβ include collagens I–V, basement membrane proteins (laminin, entactin, perlecan) and ECM proteins (fibronectin, osteopontin, thrombospontin, tenascin, osteonectin/SPARC, elastin, biglycan, decorin, and hyaluronan) (153). Additionally, in the early stages of carcinogenesis, TGFβ stimulates myofibroblasts and other stromal cells to enhance the synthesis of collagen crosslinking enzymes, particularly lysyl oxidase, which increases the rigidity of the collagen network (154). On the contrary, TGFβ downregulates the synthesis of matrix-depleting proteins, such as matrix metalloproteinases (MMP-1, -8, -13). As a result, the increase in matrix protein synthesis and decrease in matrix proteinase activity, owing to the TGFβ activity, contributes to the remodeling of the tumor ECM and can result in a fibrotic response, known as desmoplasia, which is commonly observed in many types of tumors and particularly in pancreatic, colon and breast cancers as well as in various sarcomas (155,156).
Tumor fibrotic response stiffens the tumor tissue, and as a result, it increases the compressive physical forces in the interior of the tumor (157). Compression of cancer cells alters their gene expression profile to enhance their invasive and metastatic phenotype (158,159). Furthermore, as mentioned previously, matrix stiffening along with the high contractile forces of myofibroblasts, cause further liberation of TGFβ from the LLC. These events suggest a positive feedback loop between TGFβ activation, myofibroblast contraction and ECM remodeling and production (Fig. 2A) (148). Finally, compression of intratumoral blood vessels reduces tumor perfusion, and thus, the delivery of oxygen (160). Hypo-perfusion and hypoxia, in turn contribute to immune-evasion, promote malignant progression and metastasis, and reduce the efficacy of a number of therapies including radiation treatment and systemic administration of chemo- and nanotherapy (161–163).
6. TGFβ, tumor desmoplasia and barriers to drug delivery
The desmoplastic reaction of solid tumors hinders all three transport steps of the systemic delivery of drugs, namely vascular, transvascular and interstitial transport (156,163). As mentioned above, increased levels of collagen in the ECM, result in intratumoral blood vessel compression and hypo-perfusion. Hypo-perfusion, in turn, reduces the concentration of the drug that can reach the tumor site. Apart from compromised drug delivery, hypo-perfusion also decreases the supply of oxygen rendering the tumor hypoxic, which in turn reduces the efficacy of radiation therapy. Additionally, desmoplasia reduces the hydraulic conductivity of the tumor interstitial space, i.e., the ease with which the interstitial fluid percolates through the interstitial space of a tissue. High hydraulic conductivity allows fluid to rapidly flow in the interstitial space and be drained by peripheral lymphatic vessels. The accumulation of collagen and other ECM proteins in tumors decrease the available spaces for interstitial fluid flow and because the fluid cannot freely move, the interstitial fluid pressure (IFP) increases. Interstitial hypertension is a hallmark of tumor pathophysiology. IFP reaches and even exceeds micro-vascular fluid pressure, which eliminates pressure gradients across the tumor vessel wall and thus, the transvascular transport of drugs (164). Therefore, the only mechanism of transport is through diffusion (i.e., due to a concentration difference), which is inversely proportional to the size of the therapeutic agent. Chemotherapeutic agents, with a size <1 nm, are able to diffuse fast and exit the tumor vasculature. Nanoparticles, however, with sizes >60 nm cannot effectively extravasate into the tumor interstitial space (165).
Furthermore, the dense interstitial matrix of desmoplastic tumors hinders the homogeneous distribution of large nanoparticles. As with transvascular transport, nanoparticles with a size >60 nm often cannot penetrate deep into the tumor because their size is comparable to the size of the pores of the interstitial collagen network and they often get trapped (166). Therefore, even if large nanoparticles extravassate from the leaky vessels of the tumor, they will not be able to effectively diffuse into the tissue but they will concentrate in the perivascular regions, causing only local effects. Apart from these steric interactions between the interstitial matrix and nanoparticles, the increased levels of collagen and hyaluronan give rise to electrostatic interactions. Indeed, hyaluronan has a highly negative charge, while collagen fibers carry a slight positive charge. Nanoparticles of a non-neutral surface charge density can be attracted electrostatically and bind to these proteins, which further inhibits their uniform delivery inside the tumor (167).
7. Therapeutic applications of TGFβ targeting
Pharmacological inhibition of TGFβ has been used in preclinical and clinical studies as a therapeutic strategy to either hinder tumor progression directly or modify the tumor micro-environment in order to improve perfusion and drug delivery and thus, increase indirectly the efficacy of the treatment. There is a large number of TGFβ inhibitory drugs employed in these studies (137). Particularly, targeting with TGFβ agents (e.g., 1D11, AP12009, SD-208) as well as non-specific targeting with other TGFβ inhibitory drugs (e.g., tranilast) have shown to reduce tumor progression and metastasis in vivo, mainly owing to augmentation of the immune response and inhibition of EMT (132,168–171). However, there are also studies that relate inhibition of TGFβ with promotion of tumor progression owing to an increase in inflammatory cell infiltration (172). Particularly, it has been shown that inflammatory infiltrates mediate the pro-tumorigenic functions of fibroblasts that lack TGFβ signalling. Clinical trials for the use of TGFβ inhibitory drugs have been in progress (ClinicalTrials.gov identifiers: NCT00368082, NCT01582269 and NCT00844064), but their results are not conclusive yet, presumably owing to differences in the degree of desmoplasia among tumor types or even among tumors of the same type, but also owing to the various effects of TGFβ on tumor biology.
Targeting of TGFβ to reduce desmoplasia has the ability to alleviate physical forces in tumors, decompress tumor blood vessels and improve perfusion (Fig. 2B) (160). Restoration of tumor perfusion, however, can increase nutrients supply to the tumor, and thus, increase its growth rate. Also, the decompressed vessels could allow more metastatic cells to leave the primary tumor. Indeed, in some cases, inhibition of TGFβ has been shown to facilitate tumor progression and metastases in mouse tumor models (173,174), whereas other studies, not related to TGFβ, have shown a correlation between improved perfusion and increased metastases (175,176). Therefore, based on this rationale, judicious doses of TGFβ inhibitory drugs should be used to alleviate physical forces, decompress blood vessels and improve perfusion when these agents are combined with cytotoxic treatments, such as chemo-, nano-, immuno- and radiotherapy. In these combined treatments the role of the anti-TGFβ drug is to enhance the delivery of the cytotoxic agent and thus, optimize its efficacy. This therapeutic strategy is known as stress alleviation treatment (156,163,165).
Detailed in vivo studies have shown that re-purposing the anti-hypertensive, angiotensin receptor blocker (ARB) drug losartan reduced expression of TGFβ1 and decreased stromal collagen and hyaluronan production, in doses that did not affect blood pressure. Reduction of collagen and hyaluronan, in turn, reduced stress levels in the tumor decompressing intratumoral blood vessels and improving perfusion. Furthermore, reduction of the ECM components improved the interstitial fluid flow and thus, reduced levels of IFP. Improved perfusion and reduced IFP enhanced the delivery and efficacy of chemotherapy in orthotopic breast and pancreatic murine tumor models (160). Also, in another study combined treatment of mice bearing tumors with losartan and nanomedicine (Doxil) increased the distribution of the drug and the overall survival of the mice (177). Furthermore, retrospective analyses of clinical data have shown increased survival in patients with lung or renal cancers treated with ARBs (178,179). Similar retrospective analysis has shown that patients with pancreatic ductal adenocarcinomas (PDACs) receiving ARBs survived ~6 months longer than those who did not (180). These preclinical and clinical data have led to a phase II clinical trial with losartan and FOLFIRINOX in PDAC patients (ClinicalTrials.gov identifier NCT01821729). Apart from the use of ARBs, the TGFβ neutralizing antibody 1D11 improved the distribution and efficacy of therapeutics in breast carcinomas by reducing the tumor stroma (181). Additionally, re-purposing the drug pirfenidone, a TGFβ inhibitor clinically approved for the treatment of idiopathic pulmonary fibrosis, was shown to suppress desmoplasia in mice bearing pancreatic tumors and improve the efficacy of chemotherapy (182). Apart from chemotherapy, radiation therapy has been also improved after treatment with TGFβ inhibitors. Efficacy of radiotherapy depends on the oxygenation of the tissue, which is regulated by tumor perfusion (183,184).
8. Conclusions and future perspectives
Owing to the pleiotropic effects of TGFβ on tumor microenvironment and progression, targeting TGFβ signaling to directly treat tumor growth remains controversial. Recent studies have suggested an alternative therapeutic strategy, which involves the use of anti-TGFβ agents in a stress alleviation treatment. The scope of this strategy is to hinder but not completely inhibit the activation of TGFβ ultimately aiming to reduce tumor desmoplasia and particularly the levels of collagen. As described in this review, reduced collagen levels can lead to improved delivery of both chemo- and nano-therapeutics by alleviating mechanical forces and decompressing intratumoral blood vessels. Thus, blocking of TGFβ can improve indirectly the efficacy of conventional treatments. It is promising that many anti-TGFβ agents exist that are already clinically approved for other diseases (e.g., ARBs for hypertension). Re-purposing of these drugs can lead to more effective anti-cancer therapies. Therefore, we need to identify safe and well-tolerated pharmaceutical agents that may complement the treatment regimen of cancer patients. Anti-TGFβ agents are not the only drugs that have the ability to modify the tumor microenvironment. In principle, any clinically approved agent that has the ability to reduce collagen levels could be employed as an alternative strategy. Also, collagen is not the only target for the stress alleviation treatment. Reduction of stromal cells or hyaluronan has also the potential to enhance drug delivery through the same mechanism (157).
Acknowledgements
We thank Dr Christiana Polydorou for useful discussions. This study received funding from the European Research Council under the European Union’s Seventh Framework Programme (FP7/2007-2013)/ERC grant agreement no. 336839-ReEngineeringCancer.
ReferencesDerynckRAkhurstRJDifferentiation plasticity regulated by TGF-beta family proteins in development and disease910001004200710.1038/ncb43417762890WakefieldLMHillCSBeyond TGFβ: roles of other TGFβ superfamily members in cancer13328341201310.1038/nrc350023612460MassaguéJSeoaneJWottonDSmad transcription factors1927832810200510.1101/gad.135070516322555AnnesJPMungerJSRifkinDBMaking sense of latent TGFbeta activation116217224200310.1242/jcs.00229GleizesPEBeavisRCMazzieriRShenBRifkinDBIdentification and characterization of an eight-cysteine repeat of the latent transforming growth factor-beta binding protein-1 that mediates bonding to the latent transforming growth factor-beta12712989129896199610.1074/jbc.271.47.298918939931MiyazonoKOlofssonAColosettiPHeldinCHA role of the latent TGF-beta 1-binding protein in the assembly and secretion of TGF-beta 1101091110119912022183452762SaharinenJTaipaleJKeski-OjaJAssociation of the small latent transforming growth factor-beta with an eight cysteine repeat of its binding protein LTBP-11524525319968617200449939UnsöldCHyytiäinenMBruckner-TudermanLKeski-OjaJLatent TGF-beta binding protein LTBP-1 contains three potential extracellular matrix interacting domains1141871972001NunesIGleizesPEMetzCNRifkinDBLatent transforming growth factor-beta binding protein domains involved in activation and transglutaminase-dependent cross-linking of latent transforming growth factor-beta13611511163199710.1083/jcb.136.5.115190604782132473LawrenceDAPircherRKrycève-MartinerieCJullienPNormal embryo fibroblasts release transforming growth factors in a latent form121184188198410.1002/jcp.10412101236090474CrawfordSEStellmachVMurphy-UllrichJEThrombospondin-1 is a major activator of TGF-beta1 in vivo9311591170199810.1016/S0092-8674(00)81460-99657149RibeiroSMPoczatekMSchultz-CherrySVillainMMurphy-UllrichJEThe activation sequence of thrombos-pondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor-beta2741358613593199910.1074/jbc.274.19.1358610224129DuboisCMLapriseMHBlanchetteFGentryLELeducRProcessing of transforming growth factor beta 1 precursor by human furin convertase2701061810624199510.1074/jbc.270.18.106187737999SatoYRifkinDBInhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-beta 1-like molecule by plasmin during co-culture109309315198910.1083/jcb.109.1.30925261312115489YuQStamenkovicICell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis14163176200010652271316345DerynckRZhangYFengXHSmads: transcriptional activators of TGF-beta responses95737740199810.1016/S0092-8674(00)81696-79865691MassaguéJTGF-beta signal transduction67753791199810.1146/annurev.biochem.67.1.7539759503RigginsGJThiagalingamSRozenblumEMad-related genes in the human13347349199610.1038/ng0796-3478673135LagnaGHataAHemmati-BrivanlouAMassaguéJPartnership between DPC4 and SMAD proteins in TGF-beta signalling pathways383832836199610.1038/383832a08893010NakaoAImamuraTSouchelnytskyiSTGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad41653535362199710.1093/emboj/16.17.535393119951170167HeldinCHMiyazonoKten DijkePTGF-beta signalling from cell membrane to nucleus through SMAD proteins390465471199710.1038/372849393997BierieBMosesHLTumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer6506520200610.1038/nrc192616794634LewisKAGrayPCBlountALBetaglycan binds inhibin and can mediate functional antagonism of activin signalling404411414200010.1038/3500612910746731WranaJLAttisanoLWieserRVenturaFMassaguéJMechanism of activation of the TGF-beta receptor370341347199410.1038/370341a08047140ShiYMassaguéJMechanisms of TGF-beta signaling from cell membrane to the nucleus113685700200310.1016/S0092-8674(03)00432-X12809600MiyazonoKMaedaSImamuraTBMP receptor signaling: transcriptional targets, regulation of signals, and signaling cross-talk16251263200510.1016/j.cytogfr.2005.01.00915871923DerynckRZhangYESmad-dependent and Smad-independent pathways in TGF-beta family signalling425577584200310.1038/nature0200614534577AbdollahSMacías-SilvaMTsukazakiTHayashiHAttisanoLWranaJLTbetaRI phosphorylation of Smad2 on Ser465 and Ser467 is required for Smad2-Smad4 complex formation and signaling2722767827685199710.1074/jbc.272.44.276789346908ZhangYFengXWeRDerynckRReceptor-associated Mad homologues synergize as effectors of the TGF-beta response383168172199610.1038/383168a08774881TsukazakiTChiangTADavisonAFAttisanoLWranaJLSARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor95779791199810.1016/S0092-8674(00)81701-89865696FengXHZhangYWuRYDerynckRThe tumor suppressor Smad4/DPC4 and transcriptional adaptor CBP/p300 are coactivators for smad3 in TGF-beta-induced transcriptional activation1221532163199810.1101/gad.12.14.21539679060317015JanknechtRWellsNJHunterTTGF-beta-stimulated cooperation of smad proteins with the coactivators CBP/p3001221142119199810.1101/gad.12.14.21149679056317012ItohSEricssonJNishikawaJHeldinCHten DijkePThe transcriptional co-activator P/CAF potentiates TGF-beta/Smad signaling2842914298200010.1093/nar/28.21.429111058129113149BaiRYKoesterCOuyangTSMIF, a Smad4-interacting protein that functions as a co-activator in TGFbeta signalling4181190200210.1038/ncb75311836524ChenCRKangYSiegelPMMassaguéJE2F4/5 and p107 as Smad cofactors linking the TGFbeta receptor to c-myc repression1101932200210.1016/S0092-8674(02)00801-212150994KangYChenCRMassaguéJA self-enabling TGFbeta response coupled to stress signaling: Smad engages stress response factor ATF3 for Id1 repression in epithelial cells11915926200310.1016/S1097-2765(03)00109-612718878WottonDKnoepflerPSLahertyCDEisenmanRNMassaguéJThe Smad transcriptional corepressor TGIF recruits mSin312457463200111571228AkiyoshiSInoueHHanaiJc-Ski acts as a transcriptional co-repressor in transforming growth factor-beta signaling through interaction with smads2743526935277199910.1074/jbc.274.49.3526910575014LuoKStroscheinSLWangWThe Ski oncoprotein interacts with the Smad proteins to repress TGFbeta signaling1321962206199910.1101/gad.13.17.219610485843316985StroscheinSLWangWZhouSZhouQLuoKNegative feedback regulation of TGF-beta signaling by the SnoN onco-protein286771774199910.1126/science.286.5440.77110531062SunYLiuXEatonENLaneWSLodishHFWeinbergRAInteraction of the Ski oncoprotein with Smad3 regulates TGF-beta signaling4499509199910.1016/S1097-2765(00)80201-410549282SeoaneJLeHVShenLAndersonSAMassaguéJIntegration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation117211223200410.1016/S0092-8674(04)00298-315084259PardaliKKurisakiAMorénAten DijkePKardassisDMoustakasARole of Smad proteins and transcription factor Sp1 in p21(Waf1/Cip1) regulation by transforming growth factor-beta2752924429256200010.1074/jbc.M90946719910878024ZhangYFengXHDerynckRSmad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-beta-induced transcription394909913199810.1038/298149732876LinXLiangYYSunBSmad6 recruits transcription corepressor CtBP to repress bone morphogenetic protein-induced transcription2390819093200310.1128/MCB.23.24.9081-9093.200314645520309600PengYZhaoSSongLWangMJiaoKSertad1 encodes a novel transcriptional co-activator of SMAD1 in mouse embryonic hearts441751756201310.1016/j.bbrc.2013.10.127242115893869964IzutsuKKurokawaMImaiYMakiKMitaniKHiraiHThe corepressor CtBP interacts with Evi-1 to repress transforming growth factor beta signaling9728152822200110.1182/blood.V97.9.281511313276XiQWangZZaromytidouAIA poised chromatin platform for TGF-β access to master regulators14715111524201110.1016/j.cell.2011.11.032221967283582033RossSCheungEPetrakisTGHowellMKrausWLHillCSSmads orchestrate specific histone modifications and chromatin remodeling to activate transcription2544904502200610.1038/sj.emboj.7601332169908011589990PapageorgisPLambertAWOzturkSSmad signaling is required to maintain epigenetic silencing during breast cancer progression70968978201010.1158/0008-5472.CAN-09-1872200861752946209NakaoAAfrakhteMMorénAIdentification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling389631635199710.1038/393699335507ItóhSLandströmMHermanssonATransforming growth factor beta1 induces nuclear export of inhibitory Smad72732919529201199810.1074/jbc.273.44.291959786930HayashiHAbdollahSQiuYThe MAD-related protein Smad7 associates with the TGFbeta receptor and functions as an antagonist of TGFbeta signaling8911651173199710.1016/S0092-8674(00)80303-79215638EbisawaTFukuchiMMurakamiGSmurf1 interacts with transforming growth factor-beta type I receptor through Smad7 and induces receptor degradation2761247712480200110.1074/jbc.C10000820011278251KavsakPRasmussenRKCausingCGSmad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation613651375200010.1016/S1097-2765(00)00134-9ZhangSFeiTZhangLSmad7 antagonizes transforming growth factor beta signaling in the nucleus by interfering with functional Smad-DNA complex formation2744884499200710.1128/MCB.01636-06174381441900056ZhangYENon-Smad pathways in TGF-beta signaling19128139200910.1038/cr.2008.3282635127HartsoughMTMulderKMTransforming growth factor beta activation of p44mapk in proliferating cultures of epithelial cells27071177124199510.1074/jbc.270.13.71177706248FreyRSMulderKMTGFbeta regulation of mitogen-activated protein kinases in human breast cancer cells1174150199710.1016/S0304-3835(97)00211-59233830PapageorgisPChengKOzturkSSmad4 inactivation promotes malignancy and drug resistance of colon cancer719981008201110.1158/0008-5472.CAN-09-3269212450943075468FinlayGAThannickalVJFanburgBLPaulsonKETransforming growth factor-beta 1-induced activation of the ERK pathway/activator protein-1 in human lung fibroblasts requires the autocrine induction of basic fibroblast growth factor2752765027656200010862759VinalsFPouysségurJTransforming growth factor beta1 (TGF-beta1) promotes endothelial cell survival during in vitro angiogenesis via an autocrine mechanism implicating TGF-alpha signaling2172187230200110.1128/MCB.21.21.7218-7230.20011158590599897EllenriederVHendlerSFBoeckWTransforming growth factor beta1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extra-cellular signal-regulated kinase 2 activation6142224228200111358848XieLLawBKChytilAMBrownKAAakreMEMosesHLActivation of the Erk pathway is required for TGF-beta1-induced EMT in vitro6603610200410.1593/neo.04241155483701531665LeeMKPardouxCHallMCTGF-beta activates Erk MAP kinase signalling through direct phosphorylation of ShcA2639573967200710.1038/sj.emboj.7601818176739061994119LiaoJHChenJSChaiMQZhaoSSongJGThe involvement of p38 MAPK in transforming growth factor beta1-induced apoptosis in murine hepatocytes118994200110.1038/sj.cr.729007211453551KimuraNMatsuoRShibuyaHNakashimaKTagaTBMP2-induced apoptosis is mediated by activation of the TAK1-p38 kinase pathway that is negatively regulated by Smad62751764717652200010.1074/jbc.M90862219910748100BakinAVRinehartCTomlinsonAKArteagaCLp38 mitogen-activated protein kinase is required for TGFbeta-mediated fibroblastic transdifferentiation and cell migration11531933206200212118074HocevarBABrownTLHowePHTGF-beta induces fibronectin synthesis through a c-Jun N-terminal kinase-dependent, Smad4-independent pathway1813451356199910.1093/emboj/18.5.1345100646001171224YuLHébertMCZhangYETGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses2137493759200210.1093/emboj/cdf36612110587126112YamaguchiKShirakabeKShibuyaHIdentification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction27020082011199510.1126/science.270.5244.20088533096ShimJHXiaoCPaschalAETAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo1926682681200510.1101/gad.1360605162604931283960SorrentinoAThakurNGrimsbySThe type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner1011991207200810.1038/ncb178018758450YamashitaMFatyolKJinCWangXLiuZZhangYETRAF6 mediates Smad-independent activation of JNK and p38 by TGF-beta31918924200810.1016/j.molcel.2008.09.002189224732621323ZhangLWangWHayashiYA role for MEK kinase 1 in TGF-beta/activin-induced epithelium movement and embryonic eyelid closure2244434454200310.1093/emboj/cdg44012941696202382KimKYKimBCXuZKimSJMixed lineage kinase 3 (MLK3)-activated p38 MAP kinase mediates transforming growth factor-beta-induced apoptosis in hepatoma cells2792947829484200410.1074/jbc.M31394720015069087JaffeABHallARho GTPases: biochemistry and biology21247269200510.1146/annurev.cellbio.21.020604.15072116212495BhowmickNAGhiassiMBakinATransforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism122736200110.1091/mbc.12.1.271116082030565EdlundSLandströmMHeldinCHAspenströmPTransforming growth factor-beta-induced mobilization of actin cytoskeleton requires signaling by small GTPases Cdc42 and RhoA13902914200210.1091/mbc.01-08-03981190727199608OzdamarBBoseRBarrios-RodilesMWangHRZhangYWranaJLRegulation of the polarity protein Par6 by TGFbeta receptors controls epithelial cell plasticity30716031609200510.1126/science.110571815761148BakinAVTomlinsonAKBhowmickNAMosesHLArteagaCLPhosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration2753680336810200010.1074/jbc.M00591220010969078ShinIBakinAVRodeckUBrunetAArteagaCLTransforming growth factor beta enhances epithelial cell survival via Akt-dependent regulation of FKHRL11233283339200110.1091/mbc.12.11.33281169457060258HidalgoMRowinskyEKThe rapamycin-sensitive signal transduction pathway as a target for cancer therapy1966806686200010.1038/sj.onc.1204091LamouilleSDerynckRCell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway178437451200710.1083/jcb.200611146176463962064840RobertsABWakefieldLMThe two faces of transforming growth factor beta in carcinogenesis10086218623200310.1073/pnas.163329110012861075166359TangBVuMBookerTTGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression11211161124200310.1172/JCI20031889914523048198530WakefieldLMRobertsABTGF-beta signaling: positive and negative effects on tumorigenesis122229200210.1016/S0959-437X(01)00259-311790550SiegelPMShuWCardiffRDMullerWJMassaguéJTransforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis10084308435200310.1073/pnas.093263610012808151166246SiegelPMMassaguéJCytostatic and apoptotic actions of TGF-beta in homeostasis and cancer3807821200310.1038/nrc120814557817ChoiMEBallermannBJInhibition of capillary morphogenesis and associated apoptosis by dominant negative mutant transforming growth factor-beta receptors2702114421150199510.1074/jbc.270.36.211447673146HymanKMSeghezziGPintucciGTransforming growth factor-beta1 induces apoptosis in vascular endothelial cells by activation of mitogen-activated protein kinase132173179200210.1067/msy.2002.12530412219008RichJNZhangMDattoMBBignerDDWangXFTransforming growth factor-beta-mediated p15(INK4B) induction and growth inhibition in astrocytes is SMAD3-dependent and a pathway prominently altered in human glioma cell lines2743505335058199910.1074/jbc.274.49.3505310574984YangXLetterioJJLechleiderRJTargeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta1812801291199910.1093/emboj/18.5.1280100645941171218LaihoMDeCaprioJALudlowJWLivingstonDMMassaguéJGrowth inhibition by TGF-beta linked to suppression of retinoblastoma protein phosphorylation62175185199010.1016/0092-8674(90)90251-92163767HannonGJBeachDp15INK4B is a potential effector of TGF-beta-induced cell cycle arrest371257261199410.1038/371257a08078588DattoMBLiYPanusJFHoweDJXiongYWangXFTransforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism9255455549199510.1073/pnas.92.12.5545777754641732PolyakKKatoJYSolomonMJp27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest8922199410.1101/gad.8.1.98288131PietenpolJASteinRWMoranETGF-beta 1 inhibition of c-myc transcription and growth in keratinocytes is abrogated by viral transforming proteins with pRB binding domains61777785199010.1016/0092-8674(90)90188-K2140528NortonJDID helix-loop-helix proteins in cell growth, differentiation and tumorigenesis11338973905200011058077GrotendorstGRConnective tissue growth factor: a mediator of TGF-beta action on fibroblasts8171179199710.1016/S1359-6101(97)00010-5ParkKKimSJBangYJGenetic changes in the transforming growth factor beta (TGF-beta) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-beta9187728776199410.1073/pnas.91.19.8772809072144688KimIYAhnHJZelnerDJGenetic change in transforming growth factor beta (TGF-beta) receptor type I gene correlates with insensitivity to TGF-beta 1 in human prostate cancer cells56444819968548772MarkowitzSWangJMyeroffLInactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability26813361338199510.1126/science.77618527761852RigginsGJKinzlerKWVogelsteinBThiagalingamSFrequency of Smad gene mutations in human cancers572578258019979205057SchutteMHrubanRHHedrickLDPC4 gene in various tumor types562527253019968653691EppertKSchererSWOzcelikHMADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma86543552199610.1016/S0092-8674(00)80128-28752209HahnSAHoqueATMoskalukCAHomozygous deletion map at 18q21.1 in pancreatic cancer5649049419968564959HahnSASchutteMHoqueATDPC4, a candidate tumor suppressor gene at human chromosome 18q21.1271350353199610.1126/science.271.5247.3508553070ThiagalingamSLengauerCLeachFSEvaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers13343346199610.1038/ng0796-3438673134Schwarte-WaldhoffIVolpertOVBouckNPSmad4/DPC4-mediated tumor suppression through suppression of angiogenesis9796249629200010.1073/pnas.97.17.96241094422716915KretzschmarMDoodyJTimokhinaIMassaguéJA mechanism of repression of TGFbeta/Smad signaling by oncogenic Ras13804816199910.1101/gad.13.7.80410197981316599KretzschmarMDoodyJMassaguéJOpposing BMP and EGF signalling pathways converge on the TGF-beta family mediator Smad1389618622199710.1038/393489335504MassaguéJIntegration of Smad and MAPK pathways: a link and a linker revisited1729932997200310.1101/gad.1167003GomisRRAlarcónCNadalCVan PoznakCMassaguéJC/EBPbeta at the core of the TGFbeta cytostatic response and its evasion in metastatic breast cancer cells10203214200610.1016/j.ccr.2006.07.01916959612PaduaDZhangXHWangQTGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 41336677200810.1016/j.cell.2008.01.046183949902390892ThieryJPEpithelial-mesenchymal transitions in tumour progression2442454200210.1038/nrc82212189386YangJManiSADonaherJLTwist, a master regulator of morphogenesis, plays an essential role in tumor metastasis117927939200410.1016/j.cell.2004.06.00615210113XuJLamouilleSDerynckRTGF-beta-induced epithelial to mesenchymal transition19156172200910.1038/cr.2009.519153598CanoAPérez-MorenoMARodrigoIThe transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression27683200010.1038/3500002510655586SavagnerPYamadaKMThieryJPThe zinc-finger protein slug causes desmosome dissociation, an initial and necessary step for growth factor-induced epithelial-mesenchymal transition13714031419199710.1083/jcb.137.6.140391826712132541EgerAAignerKSondereggerSDeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells2423752385200510.1038/sj.onc.120842915674322ComijnJBerxGVermassenPThe two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion712671278200110.1016/S1097-2765(01)00260-X11430829ThuaultSValcourtUPetersenMManfiolettiGHeldinCHMoustakasATransforming growth factor-beta employs HMGA2 to elicit epithelial-mesenchymal transition174175183200610.1083/jcb.200512110168318862064178ManiSAYangJBrooksMMesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers1041006910074200710.1073/pnas.0703900104175379111891217DerynckRAkhurstRJBalmainATGF-beta signaling in tumor suppression and cancer progression29117129200110.1038/ng1001-11711586292YangJWeinbergRAEpithelial-mesenchymal transition: at the crossroads of development and tumor metastasis14818829200810.1016/j.devcel.2008.05.00918539112ZhuBFukadaKZhuHKyprianouNProhibitin and cofilin are intracellular effectors of transforming growth factor beta signaling in human prostate cancer cells6686408647200610.1158/0008-5472.CAN-06-144316951178DeckersMvan DintherMBuijsJThe tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells6622022209200610.1158/0008-5472.CAN-05-356016489022KangYMassaguéJEpithelial-mesenchymal transitions: twist in development and metastasis118277279200410.1016/j.cell.2004.07.01115294153GrandeJPRole of transforming growth factor-beta in tissue injury and repair2142740199710.3181/00379727-214-440669012358SingerAJClarkRACutaneous wound healing341738746199910.1056/NEJM19990902341100610471461PickupMNovitskiySMosesHLThe roles of TGFβ in the tumour microenvironment13788799201310.1038/nrc3603241321104025940DalalBIKeownPAGreenbergAHImmunocytochemical localization of secreted transforming growth factor-beta 1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma143381389199383936161887030KingsleyLAFournierPGChirgwinJMGuiseTAMolecular biology of bone metastasis626092617200710.1158/1535-7163.MCT-07-023417938257Prud’hommeGJPathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations8710771091200710.1038/labinvest.3700669WrzesinskiSHWanYYFlavellRATransforming growth factor-beta and the immune response: implications for anti-cancer therapy1352625270200710.1158/1078-0432.CCR-07-115717875754AkhurstRJHataATargeting the TGFβ signalling pathway in disease11790811201210.1038/nrd3810230006863520610FlavellRASanjabiSWrzesinskiSHLicona-LimónPThe polarization of immune cells in the tumour environment by TGFbeta10554567201010.1038/nri2808206168103885992LaouarYSutterwalaFSGorelikLFlavellRATransforming growth factor-beta controls T helper type 1 cell development through regulation of natural killer cell interferon-gamma6600607200510.1038/ni119715852008RubtsovYPRudenskyAYTGFbeta signalling in control of T-cell-mediated self-reactivity7443453200710.1038/nri209517525753MantovaniASozzaniSLocatiMAllavenaPSicaAMacrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes23549555200210.1016/S1471-4906(02)02302-512401408GongDShiWYiSJChenHGroffenJHeisterkampNTGFβ signaling plays a critical role in promoting alternative macrophage activation1331201210.1186/1471-2172-13-31FridlenderZGSunJKimSPolarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN16183194200910.1016/j.ccr.2009.06.017197327192754404YamaguchiYTsumuraHMiwaMInabaKContrasting effects of TGF-beta 1 and TNF-alpha on the development of dendritic cells from progenitors in mouse bone marrow15144153199710.1002/stem.1501449090791RameshSWildeyGMHowePHTransforming growth factor beta (TGFbeta)-induced apoptosis: the rise & fall of Bim81117200910.4161/cc.8.1.7291MarcoeJPLimJRSchaubertKLTGF-β is responsible for NK cell immaturity during ontogeny and increased susceptibility to infection during mouse infancy13843850201210.1038/ni.2388228637523426626WipffPJRifkinDBMeisterJJHinzBMyofibroblast contraction activates latent TGF-beta1 from the extracellular matrix17913111323200710.1083/jcb.200704042180869232140013WipffPJHinzBMyofibroblasts work best under stress13121127200910.1016/j.jbmt.2008.04.03119329048TomasekJJGabbianiGHinzBChaponnierCBrownRAMyofibroblasts and mechano-regulation of connective tissue remodelling3349363200210.1038/nrm80911988769KaragiannisGSPoutahidisTErdmanSEKirschRRiddellRHDiamandisEPCancer-associated fibroblasts drive the progression of metastasis through both paracrine and mechanical pressure on cancer tissue1014031418201210.1158/1541-7786.MCR-12-030723024188PaszekMJZahirNJohnsonKRTensional homeostasis and the malignant phenotype8241254200510.1016/j.ccr.2005.08.01016169468SamuelMSLopezJIMcGheeEJActomyosin-mediated cellular tension drives increased tissue stiffness and β-catenin activation to induce epidermal hyperplasia and tumor growth19776791201110.1016/j.ccr.2011.05.008216651513115541BrantonMHKoppJBTGF-beta and fibrosis113491365199910.1016/S1286-4579(99)00250-610611762EgebladMRaschMGWeaverVMDynamic interplay between the collagen scaffold and tumor evolution22697706201010.1016/j.ceb.2010.08.015208228912948601SmithNRBakerDFarrenMTumor stromal architecture can define the intrinsic tumor response to VEGF-targeted therapy1969436956201310.1158/1078-0432.CCR-13-163724030704StylianopoulosTJainRKCombining two strategies to improve perfusion and drug delivery in solid tumors1101863218637201310.1073/pnas.1318415110241672773832007StylianopoulosTMartinJDChauhanVPCauses, consequences, and remedies for growth-induced solid stress in murine and human tumors1091510115108201210.1073/pnas.1213353109229328713458380DemouZNGene expression profiles in 3D tumor analogs indicate compressive strain differentially enhances metastatic potential3835093520201010.1007/s10439-010-0097-020559731TseJMChengGTyrrellJAMechanical compression drives cancer cells toward invasive phenotype109911916201210.1073/pnas.11189101093271885ChauhanVPMartinJDLiuHAngiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumor blood vessels42516201310.1038/ncomms3516FacciabeneAPengXHagemannISTumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells475226230201110.1038/nature1016921753853WilsonWRHayMPTargeting hypoxia in cancer therapy11393410201110.1038/nrc306421606941JainRKMartinJDStylianopoulosTThe role of mechanical forces in tumor growth and therapy16321346201410.1146/annurev-bioeng-071813-105259250147864109025JainRKStylianopoulosTDelivering nanomedicine to solid tumors7653664201010.1038/nrclinonc.2010.139208384153065247ChauhanVPJainRKStrategies for advancing cancer nanomedicine12958962201310.1038/nmat3792241504134120281PopoviZLiuWChauhanVPA nanoparticle size series for in vivo fluorescence imaging4986498652201010.1002/anie.201003142StylianopoulosTPohMZInsinNDiffusion of particles in the extracellular matrix: the effect of repulsive electrostatic interactions9913421349201010.1016/j.bpj.2010.06.016208160452931749ZhongZCarrollKDPolicarpioDAnti-transforming growth factor beta receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multi-effects on cancer, stroma, and immune cells1611911205201010.1158/1078-0432.CCR-09-163420145179UhlMAulwurmSWischhusenJSD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo6479547961200410.1158/0008-5472.CAN-04-101315520202KimSBuchlisGFridlenderZGSystemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy681024710256200810.1158/0008-5472.CAN-08-1494190748932637471ChakrabartiRSubramaniamVAbdallaSJothySPrud’hommeGJTranilast inhibits the growth and metastasis of mammary carcinoma20334345200910.1097/CAD.0b013e328327994e19322072AchyutBRBaderDARoblesAIInflammation-mediated genetic and epigenetic alterations drive cancer development in the neighboring epithelium upon stromal abrogation of TGF-β signaling9e1003251201310.1371/journal.pgen.1003251BragadoPEstradaYParikhFTGF-β2 dictates disseminated tumour cell fate in target organs through TGF-β-RIII and p38α/β signalling1513511361201310.1038/ncb2861241619344006312BiswasTGuXYangJElliesLGSunLZAttenuation of TGF-β signaling supports tumor progression of a mesenchymal-like mammary tumor cell line in a syngeneic murine model346129138201410.1016/j.canlet.2013.12.018StockmannCDoedensAWeidemannADeletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis456814818200810.1038/nature07445189977733103772RhimADMirekETAielloNMEMT and dissemination precede pancreatic tumor formation148349361201210.1016/j.cell.2011.11.025222654203266542Diop-FrimpongBChauhanVPKraneSBoucherYJainRKLosartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors10829092914201110.1073/pnas.1018892108212826073041115WilopSvon HobeSCrysandtMEsserAOsiekaRJostEImpact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy13514291435200910.1007/s00432-009-0587-319399518KeizmanDHuangPEisenbergerMAAngiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination4719551961201110.1016/j.ejca.2011.04.019216007603175366NakaiYIsayamaHIjichiHPhase I trial of gemcitabine and candesartan combination therapy in normotensive patients with advanced pancreatic cancer: GECA110314891492201210.1111/j.1349-7006.2012.02311.x22515232LiuJLiaoSDiop-FrimpongBTGF-β blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma1091661816623201210.1073/pnas.1117610109KozonoSOhuchidaKEguchiDPirfenidone inhibits pancreatic cancer desmoplasia by regulating stellate cells7323452356201310.1158/0008-5472.CAN-12-318023348422BouquetFPalAPilonesKATGFβ1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo1767546765201110.1158/1078-0432.CCR-11-0544220284903724539ZhangMKleberSRöhrichMBlockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma7171557167201110.1158/0008-5472.CAN-11-121222006998
Smad-dependent and -independent transforming growth factor β (TGFβ) pathways. TGFβ is initially synthesized and stored in the extracellular matrix (ECM) in an inactive form, as part of the large latent complex (LLC). Upon activation, the released TGFβ ligands initiate signaling by binding to TGFβRIs and TGFβRIIs. TGFβ receptors (TGFβRs) exhibit kinase activities that are necessary for transducing canonical TGFβ signaling by phosphorylating Smads2/3. Activated receptor-associated Smads can form a heterotrimeric complex with Smad4, which interacts with other co-factors in the nucleus to regulate the expression of TGFβ target genes. In addition, downstream intracellular signaling may also be transduced via auxiliary pathways including the MEK/Erk, the Rho-like GTPases, the phosphatidylinositol-4,5-bisphosphate 3-kinase/Akt (PI3K/Akt) and the p38/mitogen-activated protein kinase (MAPK) pathways to regulate biological responses such as epithelial-to-mesenchymal transition (EMT), cell adhesion, migration and survival.
Role of mechanical forces and transforming growth factor β (TGFβ) in tumor desmoplasia and vessel compression. (A) TGFβ and mechanical forces contribute to the conversion of fibroblasts to contractile myofibroblasts. Myofibroblast formation results in upregulation of extracellular matrix (ECM) proteins and leads to tumor fibrosis, matrix stiffening and desmoplasia. Increased stiffening of the matrix, in turn, increases the magnitude of the mechanical forces and contributes to further activation of TGFβ from the ECM. This creates a positive feedback loop, which gives rise to a continuous activation of TGFβ and formation of myofibroblasts. (B) Upregulation of ECM proteins and the resulting increase in mechanical forces can compress and eventually collapse intratumoral blood vessels. Alleviation of these forces with an anti-TGFβ agent has the potential to decompress vessels and thus, improve perfusion and drug delivery to solid tumors [adapted with permission from (157)].